Search
Hengrui Medicine Receives Conditional Approval for Class 1 Innovative Drug Zemitostat Tablets
2025-09-01 /
Read about 0 minute
Author：小编
Hengrui Medicine has proudly announced that its pioneering Class 1 innovative drug, Zemitostat Tablets (trade name: Airijing, formerly known as SHR2554), has secured conditional marketing approval from the National Medical Products Administration. This breakthrough medication is specifically indicated for the treatment of adult patients diagnosed with relapsed or refractory peripheral T-cell lymphoma (R/RPTCL), who have already undergone at least one prior line of systemic therapy. Zemitostat Tablets mark China's first locally developed EZH2 inhibitor, significantly addressing a long-standing gap in this critical therapeutic area.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
